Astrazeneca (AZN) Assets Average (2009 - 2026)
Astrazeneca (AZN) posted quarterly Assets Average of $114.9 billion for Q2 2026, up 5.11% year-over-year from $109.3 billion in Q2 2025, and up 0.77% quarter-over-quarter from $114.0 billion in Q1 2026.
Astrazeneca (AZN) Assets Average (2009 - 2026) Analysis & Trends
Astrazeneca's Assets Average history runs 18 years deep, the most recent figure standing at $114.9 billion for Q2 2026.
- In Q2 2026, Assets Average rose 5.11% year-over-year to $114.9 billion; the TTM figure through Jun 2026 stood at $114.9 billion (up 5.11% YoY), while the FY2025 annual figure was $109.1 billion, up 109.02% from the prior year.
- Assets Average for Q2 2026 stood at $114.9 billion, up from $114.0 billion in the prior quarter.
- The five-year high for Assets Average was $114.9 billion in Q2 2026, with the low at $48.2 billion in Q4 2023.
- The 5-year median for Assets Average is $100.9 billion (2022), against an average of $95.1 billion.
- The sharpest annual moves came in 2023 and 2024: Assets Average tumbled 49.44% in 2023, then surged 116.76% in 2024.
- Astrazeneca's Assets Average stood at $95.3 billion in 2022, then sank by 49.44% to $48.2 billion in 2023, then surged by 116.76% to $104.5 billion in 2024, then climbed by 9.37% to $114.3 billion in 2025, then gained by 0.58% to $114.9 billion in 2026.
- Business Quant data shows AZN's Assets Average at $114.9 billion in Q2 2026, $114.0 billion in Q1 2026, and $114.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114.92 Bn |
| Mar 31, 2026 | 114.04 Bn |
| Dec 31, 2025 | 114.27 Bn |
| Sep 30, 2025 | 113.44 Bn |
| Jun 30, 2025 | 109.34 Bn |
| Mar 31, 2025 | 105.14 Bn |
| Dec 31, 2024 | 104.48 Bn |
| Sep 30, 2024 | 104.63 Bn |
| Jun 30, 2024 | 103.32 Bn |
| Mar 31, 2024 | 51.30 Bn |
| Dec 31, 2023 | 48.20 Bn |
| Sep 30, 2023 | 96.31 Bn |
| Jun 30, 2023 | 96.62 Bn |
| Mar 31, 2023 | 96.59 Bn |
| Dec 31, 2022 | 95.33 Bn |
| Sep 30, 2022 | 95.38 Bn |
| Jun 30, 2022 | 98.43 Bn |
| Mar 31, 2022 | 50.19 Bn |
| Dec 31, 2021 | 53.66 Bn |
| Sep 30, 2021 | 90.43 Bn |